Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Martin S. Rhee"'
Autor:
Iro Chatzidaki, Tristan Curteis, Hannah Luedke, Dylan J. Mezzio, Martin S. Rhee, Eve McArthur, Lucy A. Eddowes
Publikováno v:
Value in Health. 26:810-822
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15e597461a5fbdbdb505dc85e9d4dc7f
https://doi.org/10.1016/j.jval.2022.12.011
https://doi.org/10.1016/j.jval.2022.12.011
Autor:
Samir K, Gupta, Mezgebe, Berhe, Gordon, Crofoot, Paul, Benson, Moti, Ramgopal, James, Sims, Cheryl, McDonald, Peter, Ruane, William E, Sanchez, Anita, Scribner, Shan-Yu, Liu, Laurie A, VanderVeen, Hadas, Dvory-Sobol, Martin S, Rhee, Jared M, Baeten, Ellen, Koenig
Publikováno v:
The Lancet HIV. 10:e15-e23
Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism, can be administered orally or subcutaneously. We so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0317c5b459d4291e6a7388719d1e4dc8
https://doi.org/10.1016/s2352-3018(22)00291-0
https://doi.org/10.1016/s2352-3018(22)00291-0
Publikováno v:
Current Opinion in HIV and AIDS. 17:15-21
This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.Lenacapavir demonstrated picomolar potency in vitro with no c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a83c6574e22d25f93d4c43e5cf038e8
https://doi.org/10.1097/coh.0000000000000713
https://doi.org/10.1097/coh.0000000000000713
Autor:
Onyema Ogbuagu, Sorana Segal-Maurer, Winai Ratanasuwan, Benoit Trottier, Jason Brunetta, Takuma Shirasaka, Ellen L Koenig, Hui Wang, Nicolas A Margot, Hadas Dvory-Sobol, Martin S Rhee, Jared Baeten, Jean-Michel Molina
Publikováno v:
Open Forum Infectious Diseases. 9
Background Lenacapavir (LEN), a potent first-in-class inhibitor of HIV-1 capsid function, is in development as a long-acting agent for treatment and prevention of HIV-1. Methods CAPELLA is an ongoing, phase 2/3 study in heavily treatment-experienced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddc93a4d34e70d1304474e42d941ffe0
https://doi.org/10.1093/ofid/ofac492.108
https://doi.org/10.1093/ofid/ofac492.108
Autor:
Iro, Chatzidaki, Tristan, Curteis, Hannah, Luedke, Dylan J, Mezzio, Martin S, Rhee, Eve, McArthur, Lucy A, Eddowes
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Heavily treatment-experienced (HTE) people with HIV (PWH) may not achieve virologic suppression (VS) with combination antiretroviral therapy due to multi-drug resistance (MDR), intolerance, and safety concerns. These PWH often receive highly individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6f7e5e91ae4e659057c8bcdeca667ab0
https://pubmed.ncbi.nlm.nih.gov/36566886
https://pubmed.ncbi.nlm.nih.gov/36566886
Autor:
Sorana, Segal-Maurer, Edwin, DeJesus, Hans-Jurgen, Stellbrink, Antonella, Castagna, Gary J, Richmond, Gary I, Sinclair, Krittaecho, Siripassorn, Peter J, Ruane, Mezgebe, Berhe, Hui, Wang, Nicolas A, Margot, Hadas, Dvory-Sobol, Robert H, Hyland, Diana M, Brainard, Martin S, Rhee, Jared M, Baeten, Jean-Michel, Molina, Mohammed, Rassool
Publikováno v:
The New England journal of medicine. 386(19)
Patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection have limited treatment options. Lenacapavir is a first-in-class capsid inhibitor that showed substantial antiviral activity in a phase 1b study.In this phase 3 tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba09545e91c9a4e35a0e7c8f074166f
https://pubmed.ncbi.nlm.nih.gov/35869309
https://pubmed.ncbi.nlm.nih.gov/35869309
Autor:
Qi Liu, Chien-Hung Chou, Eda Canales, Roman Sakowicz, Steven Bondy, Tomas Cihlar, Albert Liclican, Diana M. Brainard, Anita Niedziela-Majka, William Rowe, Nikolai Novikov, Shekeba Ahmadyar, John R. Somoza, Randall L. Halcomb, Cheryl K. McDonald, Carina E. Cannizzaro, Nicolas Margot, Debi Jin, George Stepan, Qiaoyin Wu, Eric Hu, Judy Mwangi, Stephanie A. Leavitt, Todd C. Appleby, Robert L. Anderson, Scott E. Lazerwith, Schroeder Scott D, Tse Winston C, Gediminas Brizgys, Rebecca Begley, Yili Xu, Scott Sellers, Scott A. Wolckenhauer, Wesley I. Sundquist, Derek Hansen, Philip Morganelli, Andrew Mulato, Sheila Clancy, Xiaohong Liu, Anna Chiu, Eric S. Daar, Renee R. Ram, S. Swaminathan, Anne E. Chester, Melanie H. Wong, Ya-Pei Liu, John O. Link, Michael Graupe, Luong K. Tsai, Christian Callebaut, Latesh Lad, William E. Lee, Rujuta A. Bam, Terrence Z. Cai, Bing Lu, John K. Ling, Roland D. Saito, Magdeleine Hung, Armando G. Villaseñor, Peter Ruane, Nikos Pagratis, Martin S. Rhee, David Koditek, Gordon Crofoot, Giuseppe A. Papalia, Stephen R. Yant, Rob Hyland, Helen Yu, Jim Zheng, Jennifer R. Zhang, Gary I. Sinclair, Jiayao Li, Eric Singer
Publikováno v:
Nature
Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis1–5. However, some people living with HIV who are heavily treatment-experienced have limite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5892a90808b40581a09439f9529aaaa6
https://doi.org/10.1038/s41586-020-2443-1
https://doi.org/10.1038/s41586-020-2443-1
Publikováno v:
Antimicrob Agents Chemother
Lenacapavir (LEN; GS-6207) is a potent first-in-class inhibitor of HIV-1 capsid with long-acting properties and the potential for subcutaneous dosing every 3 months or longer. In the clinic, a single subcutaneous LEN injection (20 mg to 750 mg) in pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf24493544b8c2869b4916810c595dca
https://doi.org/10.1128/aac.02057-20
https://doi.org/10.1128/aac.02057-20
Autor:
Kirsten L. White, Damian J McColl, Edwin DeJesus, Christian Callebaut, David Piontkowsky, Hui Wang, Martin S. Rhee, Paul E. Sax, Jennifer Demorin, Erin Quirk, Moupali Das, David A. Wohl, Calvin J. Cohen
Publikováno v:
Antiviral Therapy. 23:95-99
We address a data gap identified by Adams et al., of virological efficacy outcomes and emergent drug resistance in HIV-1-infected, antiretroviral treatment (ART)-naive participants with baseline (BL) viral loads (VL) >1,000,000 copies/ml. Initial ART
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9664868d3f15e46847fb12e76282b76
https://doi.org/10.3851/imp3187
https://doi.org/10.3851/imp3187
Autor:
Heather Zhang, Danielle Porter, Natella Rakhmanina, Martin S. Rhee, Jagmohan S. Batra, Yongwu Shao, Aditya H. Gaur, Cheryl Pikora, Pope Kosalaraksa, Eva Natukunda
Publikováno v:
The Lancet Child & Adolescent Health. 1:27-34
Summary Background No once-daily single-tablet regimen is available for HIV-infected children under 12 years. The single-tablet, fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a49c4dfb85e1c7af71586f59aa0db3
https://doi.org/10.1016/s2352-4642(17)30009-3
https://doi.org/10.1016/s2352-4642(17)30009-3